Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-265,792
Closed -$15.6K 4413
2026
Q1
$15.6K Buy
265,792
+249,928
+1,575% +$85.3K ﹤0.01% 3608
2025
Q4
$9.66K Sell
15,864
-163,343
-91% -$121K ﹤0.01% 3186
2025
Q3
$65.1K Buy
179,207
+150,018
+514% +$259K ﹤0.01% 2112
2025
Q2
$40.6K Sell
29,189
-21,297
-42% -$24.4K ﹤0.01% 2056
2025
Q1
$55K Buy
50,486
+22,446
+80% +$21.2K ﹤0.01% 1986
2024
Q4
$25.8K Buy
+28,040
New +$27.9K ﹤0.01% 2002
2024
Q3
Sell
-26,555
Closed -$31.1K 2325
2024
Q2
$31.1K Buy
26,555
+10,688
+67% +$14.9K ﹤0.01% 1563
2024
Q1
$27.8K Buy
+15,867
New +$27.6K ﹤0.01% 1567
2023
Q4
Sell
-21,238
Closed -$29.3K 1829
2023
Q3
$29.3K Buy
+21,238
New +$37.3K 0.01% 1338

XTX Topco's IOBT Position: Q2 2026 in Review

XTX Topco sold out of IO Biotech (IOBT) in Q2 2026, closing a stake of 265,792 shares — an estimated $15.6K sold.

XTX Topco first reported a position in IOBT in Q3 2023 and held it in 9 quarters. The position peaked at $65.1K in Q3 2025. 0 funds tracked by Wall St. Rank hold IOBT as of Q2 2026.

  • XTX Topco reported no remaining IO Biotech position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 265,792 IO Biotech shares in Q2 2026, an estimated $15.6K.
  • XTX Topco first reported a position in IO Biotech in Q3 2023 and held it in 9 quarters.
  • XTX Topco's IO Biotech position peaked at $65.1K in Q3 2025.
  • 0 funds tracked by Wall St. Rank held IO Biotech as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.